<DOC>
	<DOCNO>NCT01043510</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial investigate pharmacodynamic ( effect ) pharmacokinetic ( exposure drug ) property NN1250 ( insulin degludec , IDeg ) subject type 2 diabetes different race and/or ethnicity .</brief_summary>
	<brief_title>The Effect NN1250 Subjects With Type 2 Diabetes Different Race and/or Ethnic Origin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Either Black African American Hispanic Latino origin White Hispanic Latino origin White Hispanic Latino origin Type 2 diabetes mellitus ( diagnose clinically ) least 12 month Treated insulin least 3 month , alone combination maximum 2 oral antidiabetic drug ( OADs ) Body mass index maximum 40.0 kg/m^2 Use GLP1 receptor agonist ( exenatide , liraglutide ) , thiazolidinediones dipeptidyl peptidase4 ( DPP4 ) inhibitor within 3 month prior screen History multiple and/or severe allergy drug food history severe anaphylactic reaction Subject donate blood plasma past month 500 mL within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>